A Real World, Multi-center Study on Mother-to-child Transmission of Hepatitis B Virus in China
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50,000
- 试验地点
- 15
- 主要终点
- rate of birth defect
研究概览
简要总结
In order to evaluate the feasibility of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030, a multi-center, prospective cohorts study was conducted to investigate MTCT of HBV in China.
详细描述
A prospective, multicenter study of pregnant women with HBV infection was conducted from July 2015 up to now in a real world setting in the Shield Project stage Ⅱ. Inclusion criteria was any pregnant women with chronic HBV infection. Pregnant women were excluded if they had a positive serologic test for human immunodeficiency virus or hepatitis C virus or any co-morbidity that might reduce compliance or if they were unable or unwilling to use the mobile health application-Shield APP. Enrolled mothers and infants were prospectively followed until infant post-vaccination serologic testing (PVST) was performed at 7-12 months of age.
Demographic data, antiviral treatment history, pregnancy and labour history, co-morbidity, HBV serologic marker tests, HBV DNA tests, liver function tests, mode of delivery, neonatal characteristics (height, weight, head circumference, Apgar score and any major birth defect), breastfeeding and PVST for infants at 7-12 months of age were collected.
A mobile health application called "SHIELD" was developed and used in the Shield Project stage Ⅱ to collect data and provide support for communication between mothers and their doctors. All laboratory test reports, questionnaires and other relevant information was uploaded into SHIELD. Participants could consult with their doctors via SHIELD during the follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •pregnant women with chronic HBV infection.
排除标准
- •positive serologic test for human immunodeficiency virus or hepatitis C virus;
- •any co-morbidity that might reduce compliance;
- •unable or unwilling to use the mobile health application-Shield APP
结局指标
主要结局
rate of birth defect
时间窗: 5 years
compare rate of birth defect among children born to mothers with and without antiviral therapy during pregnancy
rate of mother-to-child transmission of HBV
时间窗: 5 years
compare rate of mother-to-child transmission of HBV among children born to mothers with and without antiviral therapy during pregnancy
次要结局
- change of HBV DNA level in mothers with antiviral therapy from baseline to withdrawal of antiviral drugs(from enrollment to delivery, assessed up to 40 weeks)
研究者
Jinlin Hou
Professor & Director
Nanfang Hospital, Southern Medical University
